Title: Use of circulating tumor DNA (ctDNA) to monitor patients undergoing total neoadjuvant treatment (TNT) for locally advanced rectal adenocarcinoma (LARC). A growing body of research underscores ...
Fourteen City of Hope sites across the U.S. participating in research using the Haystack MRD ctDNA Test in patients with breast, colorectal, ovarian, and prostate cancer SECAUCUS, N.J. and LOS ANGELES ...
SECAUCUS, N.J. and NEW BRUNSWICK, N.J., Sept. 22, 2025 /PRNewswire/ -- Haystack Oncology, a Quest Diagnostics (DGX) company, today announced a research collaboration with the Rutgers Cancer Institute ...
A blood test based from a South Baltimore lab is making treatment clearer for cancer patients. HaystackMRD, made by Haystack Oncology within Quest Diagnostics, looks for signs of cancer that ...
Oncologists face a difficult decision after surgically removing a solid tumor. Some patients harbor residual cancer cells, known as minimal residual disease (MRD), and need additional therapy to avoid ...
A growing body of research underscores the value of ctDNA-based MRD testing to identify residual or recurring cancer in solid tumors. By detecting trace amounts of tumor-derived DNA in the bloodstream ...
Quest Diagnostics DGX company, Haystack Oncology, recently announced a research collaboration with the Rutgers Cancer Institute, New Jersey's only National Cancer Institute-designated Comprehensive ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results